Trump Announces Drug Price Cuts Deal With Regeneron

President Donald Trump announced that Regeneron has agreed to offer prescription drugs at “most favored nation” pricing, a model that ties U.S. drug costs to the lowest prices available globally.

The announcement marks what the administration says is a broader shift across the pharmaceutical industry, with 17 major drugmakers—representing roughly 80 percent of the branded drug market—now agreeing to similar pricing structures for American patients.

Trump said the policy is expected to result in a significant drop in prescription drug prices, which he described as potentially the largest reduction in U.S. history.

As part of the agreement, Regeneron will offer its cholesterol drug Praluent at a reduced price, with costs dropping from approximately $537 to $225. The company also committed to applying the pricing model to future drugs and expanding access through programs like Medicaid.

The move is part of a broader effort by the administration to lower healthcare costs and increase domestic pharmaceutical production.